NanOlogy Publishes Research Articles on the Immunomodulatory Effects of its Large Surface Area Microparticle Investigational Drugs

FORT WORTH (February 14, 2024) — NanOlogy LLC, a clinical-stage oncology company, announced today the publication of two research articles on anti-tumor immunomodulation associated with its investigational drugs:

“Intratumoral Treatment of Melanoma Tumors with Large Surface Area Microparticle Paclitaxel and Synergy with Immune Checkpoint Inhibition” published on January 22, 2024 in International Journal of Nanomedicine.

The article reports the synergistic effects of intratumoral LSAM-PTX in combination with systemic administration of the programmed cell death protein antibody (anti-mPD-1) in a syngeneic murine model of melanoma.

“Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies” published on January 30, 2024 in Oncology and Therapy.

The review covers the development of large surface area microparticle paclitaxel (LSAM-PTX) and docetaxel (LSAM-DTX) for local treatment of primary carcinomas with emphasis on immunomodulation. It summarizes preclinical and clinical studies reporting reductions in tumor volume (TV) and immunomodulation in primary tumor and peripheral blood with increases in innate and adaptive immune cells and decreases in suppressor cells. The review concludes that the investigational drugs are tumoricidal, immune enhancing, and may improve solid tumor response to immune checkpoint inhibitors without additional systemic toxicity.

About NanOlogy
NanOlogy, LLC (www.nanology.us) is a private clinical-stage oncology company formed in 2015 to improve the treatment of solid tumors with investigational drugs optimized for intratumoral delivery by a proprietary particle engineering technology platform. NanOlogy clinical programs have advanced investigational drugs in multiple solid tumors including pancreas, lung, bladder, peritoneal, ovarian, prostate, and dermal cancers. The investigational drugs are covered by composition of matter patents issued in the US (9,814,685, 10,507,195, 10,993,927, and 11,123,322), and other major jurisdictions worldwide, including Canada, Europe, Japan, China, South Korea, Australia, and India valid through June 2036. The composition patents form the foundation of an extensive intellectual property portfolio of over 100 issued patents protecting NanOlogy investigational drugs, formulations, methods, and technology.

Media Contact
Dan Eramian
Opus Biotech Communications
danieleramian@comcast.net
+425-306-8716